Debomoy Lahiri, Bryan Maloney on Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
COMMENT Merck pushing forward on clinical trials for a BACE1 inhibitor in such late stages of AD is certainly puzzling, as others have already noted. It is to be expected that, once Aβ has plateaued and sufficient Aβ-related damage has been done, there will be ...